BGI Genomics Hits Day Low of CNY 38.17 Amid Price Pressure

BGI Genomics Co., Ltd., a large-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant volatility today, with the stock dropping by 8.87% as of March 23, 2026. The stock reached an intraday low of CNY 38.17, reflecting ongoing challenges in its financial performance. Over the past week, BGI Genomics has seen a decline of 13.92%, and its one-month performance shows a substantial drop of 21.72%. The company has faced a consistent downward trend, with a year-to-date performance of -15.32% and a staggering -31.37% over the past year. This underperformance is starkly contrasted with the China Shanghai Composite, which has shown a positive return of 13.33% over the same period. Financial metrics indicate that BGI Genomics has struggled with negative results for 16 consecutive quarters, alongside a concerning operating cash flow of CNY -119.31 million. The company's debt-equity ratio stands at -0.33, and it has reported a return on equity of -8.78%. These indicators highlight the challenges the company faces in maintaining its market position amidst a competitive landscape.